ATE431423T1 - Verfahren zum screening der leichten kette eines antikörpers - Google Patents

Verfahren zum screening der leichten kette eines antikörpers

Info

Publication number
ATE431423T1
ATE431423T1 AT04703920T AT04703920T ATE431423T1 AT E431423 T1 ATE431423 T1 AT E431423T1 AT 04703920 T AT04703920 T AT 04703920T AT 04703920 T AT04703920 T AT 04703920T AT E431423 T1 ATE431423 T1 AT E431423T1
Authority
AT
Austria
Prior art keywords
antibody
library
desired antigen
screening
heavy chain
Prior art date
Application number
AT04703920T
Other languages
English (en)
Inventor
Tetsuo Kojima
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE431423T1 publication Critical patent/ATE431423T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Pyrane Compounds (AREA)
AT04703920T 2003-01-21 2004-01-21 Verfahren zum screening der leichten kette eines antikörpers ATE431423T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003012648 2003-01-21
PCT/JP2004/000496 WO2004065611A1 (ja) 2003-01-21 2004-01-21 抗体の軽鎖スクリーニング方法

Publications (1)

Publication Number Publication Date
ATE431423T1 true ATE431423T1 (de) 2009-05-15

Family

ID=32767339

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04703920T ATE431423T1 (de) 2003-01-21 2004-01-21 Verfahren zum screening der leichten kette eines antikörpers

Country Status (6)

Country Link
US (1) US8337841B2 (de)
EP (1) EP1605058B1 (de)
JP (1) JP4477579B2 (de)
AT (1) ATE431423T1 (de)
DE (1) DE602004021095D1 (de)
WO (1) WO2004065611A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003087163A1 (en) * 2002-04-15 2003-10-23 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
JP4794301B2 (ja) * 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
AU2003271186A1 (en) * 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US20070281327A1 (en) * 2003-12-12 2007-12-06 Kiyotaka Nakano Methods of Screening for Modified Antibodies With Agonistic Activities
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
WO2005056605A1 (ja) * 2003-12-12 2005-06-23 Chugai Seiyaku Kabushiki Kaisha 3量体以上の受容体を認識する改変抗体
AU2006232287B2 (en) * 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
JP5057967B2 (ja) * 2005-03-31 2012-10-24 中外製薬株式会社 sc(Fv)2構造異性体
PT1876236E (pt) * 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
JP5224580B2 (ja) * 2005-06-10 2013-07-03 中外製薬株式会社 sc(Fv)2部位特異的変異体
CA2611726C (en) 2005-06-10 2017-07-11 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
KR101367544B1 (ko) * 2005-06-10 2014-02-26 추가이 세이야쿠 가부시키가이샤 메글루민을 함유하는 단백질 제제의 안정화제, 및 그의이용
AU2006300951A1 (en) * 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
EP2009101B1 (de) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
AU2009286956B2 (en) 2008-08-28 2012-12-06 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
KR102318383B1 (ko) * 2010-07-16 2021-10-27 아디맵 엘엘씨 항체 라이브러리
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
EP2825036B1 (de) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Durch histidin manipulierte leichtkettige antikörper und genetisch modifizierte nager zur erzeugung davon
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
EP3539374A1 (de) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Nicht-menschliche tiere zur expression ph-sensitiver immunoglobulinsequenzen
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
AU2013259276B2 (en) 2012-05-10 2018-03-22 Bioatla Llc Multi-specific monoclonal antibodies
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
MX2016003617A (es) * 2013-09-30 2016-07-21 Chugai Pharmaceutical Co Ltd Metodo para producir molecula de enlace al antigeno usando fago auxiliar modificado.
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
EP4050026A1 (de) 2014-04-01 2022-08-31 Adimab, LLC Verfahren zum erhalten oder identifizieren einer oder mehrerer gemeinsamer leichter ketten zur verwendung bei der herstellung eines multispezifischen antikörpers
ES2833230T3 (es) 2014-05-13 2021-06-14 Univ Pennsylvania Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定fviii的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
US20190185578A1 (en) 2016-07-29 2019-06-20 Chugai Seiyaku Kabushiki Kaisha Bispecific antibody exhibiting increased alternative fviii-cofactor-function activity
PL3509637T3 (pl) 2016-09-06 2025-03-10 Chugai Seiyaku Kabushiki Kaisha Sposoby zastosowania dwuswoistego przeciwciała, które rozpoznaje czynnik krzepnięcia IX i/lub aktywowany czynnik krzepnięcia IX oraz czynnik krzepnięcia X i/lub aktywowany czynnik krzepnięcia X
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
KR102794369B1 (ko) 2017-08-01 2025-04-15 에이비 테라퓨틱스 인코퍼레이티드 이중특이 항체 및 그의 용도
PE20210005A1 (es) 2017-09-29 2021-01-05 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno multiespecifica que tiene actividad de sustitucion de la funcion de cofactor del factor viii de coagulacion de sangre (fviii) y formulacion farmaceutica que contiene tal molecula como ingrediente activo
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
EP3561703B1 (de) * 2018-04-25 2021-01-20 Bayer AG Identifizieren der paarung von variablen domänen aus leichten und schweren ketten von antikörpern
WO2019241216A1 (en) 2018-06-14 2019-12-19 Bioatla, Llc Multi-specific antibody constructs
JPWO2019244973A1 (ja) 2018-06-20 2021-07-08 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
US12463463B2 (en) 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
WO2020205504A1 (en) * 2019-03-29 2020-10-08 Compass Therapeutics Llc Common light chains and methods of use
WO2020246563A1 (ja) 2019-06-05 2020-12-10 中外製薬株式会社 抗体切断部位結合分子
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
CN116194124A (zh) 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
WO2025154793A1 (ja) * 2024-01-19 2025-07-24 株式会社ペルセウスプロテオミクス 多重特異性抗体の製造に使用するための共通のl鎖を同定する方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0871673B1 (de) 1995-05-03 2006-04-05 Bioenhancementsments Ltd. Bispezifische antikörper in denen die bindungsfähigkeit durch eine mittels licht spaltbare gruppe reversibel inhibiert wird
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
JP2003516744A (ja) 1999-12-14 2003-05-20 ザ バーナム インスティチュート Bcl−gポリペプチド、それをコードする核酸および使用方法
CA2404216A1 (en) 2000-03-22 2001-09-27 Curagen Corporation Novel polypeptides, and nucleic acids encoding the same
AU2001297872B2 (en) * 2000-11-17 2006-11-09 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
DK1399484T3 (da) * 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
WO2003087163A1 (en) 2002-04-15 2003-10-23 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
DK2314629T4 (da) * 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
JP4794301B2 (ja) * 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法

Also Published As

Publication number Publication date
EP1605058A4 (de) 2006-04-19
JP4477579B2 (ja) 2010-06-09
EP1605058B1 (de) 2009-05-13
JPWO2004065611A1 (ja) 2006-05-18
US20060159673A1 (en) 2006-07-20
DE602004021095D1 (de) 2009-06-25
WO2004065611A1 (ja) 2004-08-05
US8337841B2 (en) 2012-12-25
EP1605058A1 (de) 2005-12-14

Similar Documents

Publication Publication Date Title
ATE431423T1 (de) Verfahren zum screening der leichten kette eines antikörpers
MX2009013327A (es) Ingenieria basada en secuencias y optimizacion de anticuerpos de cadena simple.
EP3202786A3 (de) Sequenzbasierte herstellung und optimierung von einzelkettenantikörpern
NO20052181D0 (no) Fremgangsmate og apparat for a posisjonere et sentrum for en seismisk kilde
TW200516083A (en) Methods for making dual specificity antibodies
ES2641294T3 (es) Nuevo anticuerpo para el diagnóstico y/o el pronóstico del cáncer
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
ATE503239T1 (de) Verfahren zur synthetisierung eines virtuellen bildes durch strahlabgabe
NO20083171L (no) Ny samling av HCDR3 omrader og anvendelser derav
ATE408684T1 (de) Verfahren zur verbesserung von t-zellrezeptoren
WO2005072112A3 (en) Methods for producing and identifying multispecific antibodies
DK1716181T3 (da) CDR-reparerede antistoffer
CY1111966T1 (el) Αντισωματα που δεσμευονται με κυτταροσυνδετο ca 125/0722ρ και μεθοδοι χρησεις αυτων
AR083747A1 (es) Anticuerpos anti-il-23
PE20110797A1 (es) Anticuerpos anti mn
WO2010036851A3 (en) Single chain antibody library design
ATE366421T1 (de) Verfahren zur 3d-vorhersage von reflexionen an der freien oberfläche
WO2010049672A3 (en) Methods and products for measuring free immunoglobulin light chain molecules
ATE546524T1 (de) Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür
DE60130211D1 (de) Matrix-screening-verfahren
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering
IL164625A (en) Method for producing a plurality of monoclonal antibodies and method for identifying a plurality of monoclonal antibodies
DE602006021324D1 (de) Verfahren zur herstellung stabiler b-lymphozyten
Manrique et al. Anuran call synthesis with diffusion models for enhanced bioacoustic classification under data scarcity
WO2005049652A3 (en) Methods of generating antibody diversity in vitro

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties